Most Recent Articles by Brian Ellis
Many in the medical field are wondering whether now may be the right time for medical malpractice reform.
Analyses of the ARM-TD and AIM-TD trials indicate that deutetrabenazine performs better than placebo as treatment for tardive dyskinesia.
Four-year results show that motor complications, but not burden of nonmotor symptoms, can predict death in patients with Parkinson's disease.
New research suggests that baseline gut microbiota may predict the progression of Parkinson's disease at 2 years.
Pulse pressure was associated with the risk for ischemic stroke in first-ever ischemic stroke patients old than 60 years.
More Articles by Brian Ellis
Neurology Advisor Articles
- McDonald Criteria Update: Further Distinction Between Relapsing-Remitting, Primary-Progressive MS
- Distinct Clinical Characteristics of Headache Associated With Subarachnoid Hemorrhage
- Increased Epilepsy Risk Identified in Multiple Sclerosis
- Magnesium Plus Environmental Enrichment Boosts Cognition, Memory in Alzheimer's Mouse Model
- Prognostic Significance of Weight Loss in Patients With Early Parkinsonism
- Coffee Consumption May Decrease Stroke Risk
- When and How to Approach Driving Cessation in Patients With Dementia
- NBT System Gets FDA Clearance for Depression Treatment
- Erenumab, Fremanezumab Reduce Migraine Frequency, Burden
- Some Antiepileptic Drugs Associated With Increased Risk for Toxic Epidermal Necrolysis
- Obesity and Alzheimer Disease: Exploring Risk Modification
- Increased Amyloid Burden With Obstructive Sleep Apnea
- Vigabatrin Beneficial for Focal Seizures in Tuberous Sclerosis Complex
- Number of Americans With Alzheimer Disease Expected to More Than Double by 2060
- Deep Brain Stimulation Improves Survival in Parkinson Disease